Evidence map›Paper›PMID 40655978›Full record

ArticleNeuroscience applied2023

Polymorphisms in the adrenergic neurotransmission pathway impact antidepressant response in depressed patients.

Taichi Ochi, Natalya M Vyalova, Innokentiy S Losenkov, Diana Z Paderina, Ivan V Pozhidaev, Anton J M Loonen, German G Simutkin, Nikolay A Bokhan, Bob Wilffert, Svetlana A Ivanova

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuroscience applied, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Brain Iron Homeostasis and Mental Disorders.Antioxidants (Basel, Switzerland) · 2023
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Taichi OchiDepartment of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, the Netherlands.
Natalya M VyalovaMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.
Innokentiy S LosenkovMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.
Diana Z PaderinaMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.
Ivan V PozhidaevMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.
Anton J M LoonenDepartment of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, the Netherlands.
German G SimutkinMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.
Nikolay A BokhanMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.
Bob WilffertDepartment of PharmacoTherapy, -Epidemiology and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713AV, Groningen, the Netherlands.
Svetlana A IvanovaMental Health Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, Aleutskaya str., 4, Tomsk, 634014, Russian Federation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mood disorders are a prevalent mental health disorder. The adrenergic neurotransmission pathway presents an opportunity to determine whether genetic mutations impact antidepressant response. For this study, 163 patients with major depressive disorders were enrolled to measure treatment response using the Hamilton Depression Rating Scale (HAMD-17). More than half of the patients had never been treated with antidepressants previously. Patients were genotyped for 14 SNPs within

Indexed as

Adrenergic neurotransmissionAntidepressantsHabenulaMajor depressive disorderPharmacogeneticsTreatment response

Identifiers

PMID40655978
PMCPMC12243976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.